Ortec CCS Venous Leg Ulcer PMA Due 2002; Panel Will Review Burn Indication
This article was originally published in The Gray Sheet
Executive Summary
Ortec International plans to file a PMA supplement for its composite cultured skin (CCS) for venous skin ulcer treatment by mid-2002, according to company officials.
You may also be interested in...
Bioheart Pursues OrCel Cardiac Regeneration; Ortec Chases Ulcer Claims
Bioheart, Inc.'s Myocell may provide Ortec entry into the cardiovascular regeneration market, under a deal covering the cell transplantation product in combination with Ortec's OrCel collagen sponge and vascular endothelial growth factor technologies
Bioheart Pursues OrCel Cardiac Regeneration; Ortec Chases Ulcer Claims
Bioheart, Inc.'s Myocell may provide Ortec entry into the cardiovascular regeneration market, under a deal covering the cell transplantation product in combination with Ortec's OrCel collagen sponge and vascular endothelial growth factor technologies
ATS Dermagraft Approval Breaks Apligraf Monopoly In Chronic Wounds
Advanced Tissue Sciences plans a PMA supplement supported by an ongoing 240-patient U.S. trial for expanded use of its Dermagraft tissue-engineered, living dermal substitute to treat venous ulcers. FDA approval for diabetic foot ulcers was received Sept. 28.